- FTX disputes the $264 million claim by Jump Trading over SRM tokens.
- Allegations include non-delivery and questionable damages calculation methodology.
The FTX bankruptcy estate is disputing a $264 million claim by Tai Mo Shan, a subsidiary of Jump Trading, related to a loan agreement with Alameda Research involving 800 million Serum (SRM) tokens. SRM served as the cryptocurrency for Serum, a decentralized exchange once affiliated with FTX, which collapsed following FTX’s bankruptcy in 2022.
Jump Trading asserts damages based on an options model, factoring in SRM‘s market price during the bankruptcy filing, implied volatility, and other financial metrics. However, FTX’s legal team argues that Alameda Research never fulfilled the loan agreement by delivering the SRM tokens. Thereby invalidating Tai Mo Shan’s claim.
And, they contend that since the loan did not commence due to non-delivery, Tai Mo Shan lacks grounds to seek damages under the agreement.
Questioning Jump Trading
FTX further challenges the validity of the $264 million damages calculation, describing it as unsupported and vague. It questioned the methodology of Jump Trading‘s options model. They also suggest Tai Mo Shan may have engaged in potentially fraudulent transfers, complicating the claim further.
Amidst these legal disputes, FTX is focused on finalizing a liquidation plan to compensate exchange customers, with creditor voting ongoing. And a plan approval targeted for October. The outcome of these proceedings will likely shape the resolution of financial claims against FTX and its affiliated entities.
Highlighted News Of The Day
